Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
  • TickerBAY001
  • ISINDE000BAY0017
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany

Analysts

Research Department

INFORME DIARIO 12 AGOSTO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME. ESPAÑA: IBERDROLA, MÁSMÓVIL. EUROPA: BAYER. Caídas moderadas con poco volumen a la espera de acontecimientos Las bolsas europeas se mantuvieron con pérdidas moderadas y ya con menos volumen (ante la ausencia de noticas) durante toda la sesión. En el Euro STOXX Farma (nuevamente impulsado por Bayer, esta vez ante la expectativa de acuerdo sobre el Glifosato) e Inmobiliario fueron los únicos sectores en cerrar en positivo, mientras que los cíclicos, liderados nuevamente por R. Básicos y Autos, junto con Bancos (lastrados por los italianos ante el repunte d...

Research Department

INFORME DIARIO 08 AGOSTO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME. ESPAÑA: ARCELOR MITTAL, BBVA, FERROVIAL. EUROPA: ADIDAS, ALLIANZ, BAYER, DEUTSCHE TELEKOM, SIEMENS. Rebote técnico de las bolsas europeas sin mejora de perspectivas que actúe de catalizador Las bolsas europeas mantuvieron modestas ganancias durante toda la jornada. En el Euro STOXX los sectores ligados a materias primas siguieron acusando con caídas la debilidad del yuan y las dudas sobre el crecimiento, así R. Básicos y Energía lideraron las caídas junto con Bancos (ante una nueva caída de las rentabilidades soberanas), Ocio fue el sector con mayores s...

Oscar Rodriguez

BAYER: RETRASAN EL JUICIO SOBRE EL GLIFOSATO HASTA 1T20 (ANÁLISIS BANCO SABADELL)

Según Bloomberg, el juicio que estaba previsto realizarse en St. Louis en 3T'19 en relación a un caso vinculado al Glifosato podría posponerse a 1T'20. VALORACIÓN Noticia positiva para BAY (y así lo recoge la acción con una subida del +7% vs +1,3% del ES50), ya que cualquier retraso se interpreta como una menor solidez en las pruebas presentadas por la acusación y podría permitir a la compañía salir victoriosa en un proceso por primera vez desde que se iniciaron los litigios vinculados al Glifosato. En nuestra opinión, un resultado favorable a BAY en un juicio creemos que sería netamente posit...

Research Department

INFORME DIARIO 07 AGOSTO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME. ESPAÑA: COLONIAL, SECTOR ELECTRICO Y GASISTA. EUROPA: AHOLD, BAYER, MUNICH RE, UNICREDIT, VIVENDI La estabilización del yuan da cierto respiro a las bolsas. Tras la fuerte corrección de las sesiones anteriores, las bolsas europeas se mantuvieron prácticamente planas durante toda la sesión gracias a la estabilización del yuan (con las medias del PBoC) que evitan una nueva escalada en el conflicto comercial entre EE.UU. y China. En el Euro STOXX R. Básicos volvió a ser el más castigado junto con Energía (caída del crudo por debajo de 60 dólares) mientras q...

Nurhayati Wan

Bayer AG

Bayer AG - December 2017 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Bayer AG: Update to Discussion of Key Credit Factors

A detailed rationale for Bayer’s rating review for downgrade prompted by its offer to acquire Monsanto which would lead to significant increase in leverage.

Bayer AG - September 2017 (LTM): Peer Snapshot

Peer Snapshot:  Bayer AG - September 2017 (LTM) 1 December 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM Jun-17

Bayer AG - June 2017 (LTM): Peer Snapshot

Peer Snapshot: Bayer AG - June 2017 (LTM) 31 August 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Jun-17 FYE Dec-15 FYE Dec-16 LTM Jun-17 FYE Dec-15 FYE Dec-16 LTM Mar-17

Bayer AG: Update to Discussion of Key Credit Factors

CORPORATES CREDIT OPINION 3 July 2017 Update RATINGS Bayer AG Domicile Germany Long Term Rating A3 , Possible Downgrade Type Senior Unsecured - Fgn Curr Outlook Rating(s) Under Review Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Francois Lauras 44-20-7772-5397 VP-Sr Credit Offic

Oscar Rodriguez

BAYER: RETRASAN EL JUICIO SOBRE EL GLIFOSATO HASTA 1T20 (ANÁLISIS BANCO SABADELL)

Según Bloomberg, el juicio que estaba previsto realizarse en St. Louis en 3T'19 en relación a un caso vinculado al Glifosato podría posponerse a 1T'20. VALORACIÓN Noticia positiva para BAY (y así lo recoge la acción con una subida del +7% vs +1,3% del ES50), ya que cualquier retraso se interpreta como una menor solidez en las pruebas presentadas por la acusación y podría permitir a la compañía salir victoriosa en un proceso por primera vez desde que se iniciaron los litigios vinculados al Glifosato. En nuestra opinión, un resultado favorable a BAY en un juicio creemos que sería netamente posit...

Oscar Rodriguez

BAYER: MENSAJES DE LA CONFERENCE CALL RDOS. 2T19 (ANÁLISIS BANCO SABADELL)

BAYER: MENSAJES DE LA CONFERENCE CALL RDOS. 2T19 (ANÁLISIS BANCO SABADELL)

Jean-Jacques Le Fur

BAYER: Q2 2019 results below CS and a masked warning | SELL | EUR66(+12%)

BAYER - SELL | EUR66(+12%) Q2 2019 results below CS and a masked warning A difficult Q2 in Crop Sciences and 2019 guidance now a challenge Crop Science: negatively impacted in the US Pharmaceuticals sales in line with consensus Consumer Health: some light at the end of the tunnel? No change to our rating

Damien Conover

Morningstar | Jury Awards Over $2B in Damages Against Bayer in Glyphosate Case, but Lower Costs Likely on Appeal

A jury in Northern California decided Bayer's glyphosate product caused cancer in two more people and awarded close to $2 billion in damages, but we are not changing our moat rating or fair value based on the ruling. We expect Bayer will appeal this case, with a much more favorable outcome likely. As the majority of the damages were punitive (relative to compensatory), we also expect subsequent decisions to significantly lower the amount of damages. We continue to view the stock as undervalued, but we also continue to rate the stock with a high uncertainty (the highest rating in the peer group...

Damien Conover

Jury Awards Over $2B in Damages Against Bayer in Glyphosate Case, but Lower Costs Likely on Appeal

A jury in Northern California decided Bayer's glyphosate product caused cancer in two more people and awarded close to $2 billion in damages, but we are not changing our moat rating or fair value based on the ruling. We expect Bayer will appeal this case, with a much more favorable outcome likely. As the majority of the damages were punitive (relative to compensatory), we also expect subsequent decisions to significantly lower the amount of damages. We continue to view the stock as undervalued, ...

1 director bought

A director at Bayer Ag bought 2,000 shares at 59.480EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Nurhayati Wan

Bayer AG

An increasingly favourable environment allows BAYER AG to improve to Neutral

The independent financial analyst theScreener just upgraded the general evaluation of BAYER AG (DE), a company active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date July 2, 2019, the closing price was EUR 60.50 and its expected value was estimated at EUR 56.51.

Nurhayati Wan

Bayer AG

Nurhayati Wan

Bayer AG

Nurhayati Wan

Bayer AG

Expert Corporate Governance Service (ECGS)

Bayer - 26 April 2019 AGM

Items 2 and 3: On 7 June 2018, Bayer closed the acquisition of Monsanto for USD 63bn, including debt, the biggest acquisition in Bayer's history. As of 28 January 2019, lawsuits from approximately 11,200 plaintiffs claiming to have been exposed to glyphosate-based products manufactured by Monsanto had been served in the United States. Since the closing of the merger, Bayer's market capitalisation decreased by almost 42% from EUR 92.3bn to EUR 53.7bn between 7 June 2018 and 29 March 2019. This was a critical destruction of shareholder value, ultimately caused by the Management Board's decision ...

Bayer – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Proxy Report - 25/05/2018

General: On 14 September 2016, Bayer signed a definitive merger agreement with Monsanto Company, which provides for Bayer’s acquisition of all outstanding shares in Monsanto against a cash payment of USD 128.00 per share, see section 3.1 for details. Under German law, the transaction is not subject to shareholder approval. The shareholders of Monsanto approved the merger with the requisite majority on 13 December 2016. However, the transaction remains subject to customary closing conditions, including relevant antitrust and other regulatory approvals. The European Commission, has approved the ...

Expert Corporate Governance Service (ECGS)

Proxy Report - 25/05/2018

General: On 14 September 2016, Bayer signed a definitive merger agreement with Monsanto Company, which provides for Bayer’s acquisition of all outstanding shares in Monsanto against a cash payment of USD 128.00 per share, see section 3.1 for details. Under German law, the transaction is not subject to shareholder approval. The shareholders of Monsanto approved the merger with the requisite majority on 13 December 2016. However, the transaction remains subject to customary closing conditions, including relevant antitrust and other regulatory approvals. The European Commission, has approved the ...

Jérôme VINERIER

Analyse court terme - BAYER : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 66,62 €, puis 59,12 €. Le franchissement de 85,70 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - BAYER : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €66.62, then €59.12. Passing €85.70 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - BAYER : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 66,62 €, puis 59,12 €. Le franchissement de 85,70 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - BAYER : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €66.62, then €59.12. Passing €85.70 would question the continuation of the fall.

Jérôme VINERIER

Medium term view - BAYER : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €66.20, then €49.50. Passing €102.90 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch